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Abstract
COPD is a disease of innate immunity and bacterial infections are a dominant cause of exacerbations in the later
stages resulting in poor health and high mortality. The pathogen-associated molecular pattern (PAMP)
lipopolysaccharide (LPS) is sensed by immune cells through activation of the toll-like receptor 4 (TLR4). This leads
to the activation of NADPH oxidase (NOX) and NF-B which together drive COPD inflammation. In this study we
show in human PBMCs that LPS stimulated proinflammatory cytokine release (CXCL8 and IL6) was inhibited by
approximately 50% by the broad specificity phosphatidylinositol 3-kinase (PI3K) inhibitor, wortmannin. Our results
also demonstrate that activation of PI3K following LPS stimulation is mediated by a NOX4 dependent mechanism
releasing endogenous H2O2, as the NOX4 inhibitor apocynin blocked LPS induced AKT phosphorylation. Moreover,
LPS-induced PI3K activation was inhibited by the anti-oxidant N-acetylcysteine in a concentration dependent
manner (IC50 ~100 μM). In addition, our data demonstrated that inhibition of small G proteins, by pre-treatment
with pertussis toxin, inhibited LPS-induced AKT phosphorylation. Furthermore, the G-protein inhibitors pertussis
toxin and mastoparan both inhibited LPS-induced CXCL8 and IL-6 release by approximately 50%. Together, these
data indicate there is a mechanism in human PBMCs where TLR4 activation by LPS leads to ROS generation
through NOX4 and activation of the PI3K pathway. This effect is apparently mediated through small G proteins
facilitating the release of pro-inflammatory cytokines.
Introduction
Bacterial infections are one of the dominant causes of
acute exacerbations in chronic obstructive pulmonary
disease (COPD). Lipopolysaccharide (LPS) is the most
abundant component within the cell wall of Gram-nega-
tive bacteria. It can stimulate the release of interleukin 8
(IL-8, CXCL8, CXC ligand 8) and other inflammatory
cytokines in various cell types, leading to an acute
inflammatory response towards pathogens [1]. These
responses are initiated by the activation of the TLR sig-
nalling through adaptor proteins, and include induction
of gene expression via the activation of the NF-Ba n d
AP-1 signal transduction pathways [2]. Bacterial LPS has
been extensively used in models studying inflammation
as it mimics many inflammatory effects of cytokines,
such as TNF-a,I L - 1 b or IL-6. The cellular receptor
transducing the LPS signal has been identified as Toll-
like receptor 4 (TLR4) [3-5]. Binding of LPS to TLR4
leads to the activation of NF-Bt h r o u g ht h er e c r u i t -
ment and activation of MyD88, IL-1R kinase (IRAK),
TNFR associated factor 6 (TRAF-6), as well as NADPH
oxidase (Nox) [2,6,7]. NF-B plays a crucial role in regu-
lating the transcription of genes related to innate immu-
nity and inflammation responses and several studies
indicate its activation is controlled by reactive oxygen
species (ROS) in immune modulation in the lungs and
in monocytes [8-11].
Several studies searching for novel anti-inflammatory
agents have led to the identification of a key role for
phosphatidylinositol 3-kinase (PI3K) in transducing
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chronic inflammatory diseases, such as COPD [12]. The
PI3K family is divided into three classes (I, II and III)
depending on their structure, substrate and function
[13]. The class I PI3Ks are further subdivided into class
IA (p110a, p110b and p110δ)a n dc l a s sI B( p 1 1 0 g). All
class I PI3Ks mediate fundamental signalling pathways
and cellular processes that orchestrate cell growth, pro-
liferation, migration and survival [14]. Class IA PI3Ks
are activated via cell surface expressed receptor tyrosine
kinases (RTKs) including insulin and growth factors
whereas, class IB (p110g) are activated by G-protein
coupled receptors (both a and bg subunits of G-pro-
teins) [15,16]. There is clear evidence that PI3Ks (PI3Kg
and PI3Kδ) play a crucial role in mediating both the
innate and adaptive immune response by regulating leu-
kocyte migration, activation and antigen response
[17-19]. PI3K activation is important for neutrophil
migration [20,21] and this can play a significant role in
disease exacerbations where neutrophilic influx is evi-
dent, as observed in COPD.
Several studies have shown that activation of PI3Ks by
many microbial stimuli such as LPS, play a key role in
regulating immune cell mechanisms, such as cytokine
production [22,23]. Moreover, global inhibition of the
various PI3-kinase isoforms interferes with the TLR-
mediated cellular signalling pathways and molecular
responses such as B cell cytokine production and differ-
entiation [24,25]. However, the molecular mechanism by
which LPS induces cytokine release in human mono-
cytes is not fully understood and therefore warrants
further investigation. In this study we demonstrate that
LPS-stimulated release of proinflammatory cytokines
from human monocytes is mediated through the activa-
tion of PI3K in both a ROS- and a G-protein-dependent
manner, propagated through NOX4 activation.
Methods
Isolation of human peripheral blood mononuclear cells
(PBMCs) and monocytes
PBMCs from healthy volunteers were isolated by centri-
fugation of whole blood on Histopaque
®-1077 (Sigma;
Poole, Dorset, UK) at 400 g for 30 min at room tem-
perature. Cells collected from the interphase were
washed with PBS then resuspended in RPMI-1640 med-
ium supplemented with 10% heat-inactivated fetal
bovine serum and 2 ml L-glutamine. Human monocytes
were purified by allowing the purified PBMCs resus-
pended in IMDM at 4 × 10
6 cells/ml to adhere to tissue
culture plates for 1-2 hours at +37°C. Non-adherent
cells were removed with warm HBSS twice before
detaching adherent cells (> 90% monocytes) with cell
dissociation buffer (Gibco BRL; Paisley, UK). The har-
vested monocytes were then resuspended in IMDM
with 1% (w/v) BSA ready for the chemotaxis assay. The
population of monocytes harvested by this method has
been described previously [26] and the purity of the
population was more than 95%. The study was approved
by the local Ethics Committee with informed consent
obtained from each participant.
Cell Culture and Treatments
Purified PBMCs were pre-treated with pharmacological
agents as indicated in figure legends for 30 min before
stimulation with LPS (100 ng/ml) for further 15 min
prior to cell lysis and assessment of pAKT/Total AKT
by either MSD assay (Mesoscale; Gaithersburg, MD) or
immunoblotting. Alternatively, following the addition of
LPS, the PBMCs were left to incubate for 16 hours at
+37°C before culture supernatants were removed and
assessed for both IL-6 and CXCL8 by sandwich enzyme-
linked immunosorbent assay (R&D Systems; Abingdon,
UK) according to the manufacturer’s protocols.
Chemotaxis assay: (plate based assay)
Chemotaxis was assessed as previously described [27].
Briefly, monocytes were pre-loaded with Calcein-AM
at 5 μg/10
7 cells for 20 min at +37°C, then resus-
pended in IMDM supplemented with 0.1% w/v BSA at
8×1 0
6 cells/ml and kept on ice in the dark until
needed. Into the bottom well of a 96 well Neuroprobe
5 μM chemotaxis plate (Receptor Technologies Ltd;
Adderbury, UK) was placed 29 μlo f3n MC 5 ai n
medium (IMDM + 0.1% BSA), medium only (back-
ground) or cells in medium only (maximum signal).
Into the upper chamber, 25 μl of calcein loaded cells
were applied and the plate left to incubate for 90 min
at +37°C. After 90 min unmigrated cells were washed
away from the top chamber with PBS and the plate
read using a Fluoroskan II plate reader (Labsystems,
Cambridge, UK) in bottom reading mode (Ex 485 nm,
Em 538 nm).
Measurement of AKT/pAKT by MSD assay
Phospho (Ser473) AKT and total AKT was evaluated
using the MSD
®MULTI-SPOT assay system from
Mesoscale (Gaithersburg, MD. Cat # K15100D). PBMCs
were aliquoted into a 96 well tissue culture plate at
3
x10
6 cells/well then incubated with or without wort-
mannin or N-acetylcysteine for 30 min before treating
the cells with 100 ng/ml LPS for a further 15 min. Cells
were pelleted at 500 g for 3 minutes at +4°C and washed
once with ice cold PBS before pelleting again and lysing
the cell pellet with 100 μl ice cold lysis solution pro-
vided in the MSD assay kit. 20 μg of protein cell lysate
was transferred to a 96 well MSD plate and phosphor-
AKT and total AKT were assessed as per manufacturer’s
instructions.
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All experimental details are according to previous
description (28). Whole Cell protein extracts were pre-
pared using modified RIPA buffer (50 mM Tris HCL
pH7.4. 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycho-
late, 1% CHAPS, 1 mM EDTA with freshly added com-
plete protease and phosphatase inhibitor cocktail II
(Calbiochem; Feltham, UK). Protein concentration was
determined using the Pierce BCA protein assay kit
(Rockford, IL). Whole cell lysates were subjected to wes-
tern blot after SDS PAGE using mouse monoclonal anti-
phosphoAKT (Abcam; Cambridge, UK). Western Blots
were stripped with Chemicon Re-Blot Plus western recy-
cling kit (Chemicon International, Temecula, CA),
blocked and reprobed with anti-AKT (Abcam). All other
reagents were from Sigma (Poole, UK) unless otherwise
stated.
Statistical analysis
Data were analysed by means of 1-way ANOVA to
determine statistically significant variance between the
groups for each end point assessed. Statistical signifi-
cance between groups was then calculated by using the
nonparametric Mann-Whitney t test with GraphPad
Prism software (GraphPad Software, Inc, La Jolla, Calif).
Data are expressed as means ± SEMs. Differences were
considered significant at a P value of less than 0.01.
Results
LPS-induced IL-6 and CXCL8 release is blocked by
inhibition of PI3K
The impact of the general PI3K inhibitor wortmannin
on CXCL8 and IL-6 release from LPS treated PBMC is
displayed in Figure 1. Wortmannin inhibits both IL-6
and CXCL8 release in a concentration-dependent man-
ner. Wortmannin inhibits the PI3kinase with an IC50 of
1 nM to 10 nM and did not affect affect cell viability up
to a concentration of 10
-6M. However, in both cases
wortmannin at the highest concentrations used (1000
nM) was only able to inhibit approximately 50% of the
total CXCL8 and IL-6 response induced by LPS. In con-
trast, wortmannin can be seen to completely block C5a
induced monocyte chemotaxis, a PI3K-dependent func-
tional response (Figure 2).
LPS-induced phosphorylation of AKT is inhibited by
wortmannin and N-acetylcysteine
LPS stimulation of PBMCs induced phosphorylation of
AKT after only 15 minutes and this was maximal by 30
minutes (Figure 3). All further experiments therefore
investigated Akt phosphorylation after only 15 minutes
treatment of PBMCs with LPS. Wortmannin shows a
concentration dependent inhibition of LPS-induced
phospho-AKT (pAKT) expression with an IC50 of 1 nM
(Figure 4a). Inhibition of LPS-induced pAKT is com-
plete with levels returning to those seen under basal
conditions. In contrast, the anti-oxidant N-acetylcysteine
was only able to inhibit LPS-induced pAKT expression
by 50% at the highest concentration tested, 300 μM
(Figure 4b). Nevertheless, N-acetylcysteine did show a
concentration dependent inhibition of pAKT expression
with an IC50 of around 100 μM.
LPS induced inflammation is modulated through Gi-
dependent signalling
The small G-protein inhibitor pertussis toxin and the
specific Gia inhibitor ‘mastoparan’ inhibit Gia with an
IC50 of approximately 200 pg/ml [28] and 15 μM [29]
Figure 1 Impact of the PI3K inhibitor wortmannin on LPS-induced release of CXCL8 and IL-6. Purified human PBMCs were treated with
100 ng/ml LPS in the presence of wortmannin for 16 hrs. CXCL8 (a) and IL-6 (b) were assessed by ELISA and the data normalised to control
(LPS stimulation only) for each experiment. The mean ± SEM for each data point from at least 3 independent experiments is shown. Sigmoidal
dose response curves were plotted using Prism4 software. 100% of control (LPS-stimulated PBMCs only) represented 15 ng/ml CXCL8 and 30 ng/
ml IL-6 respectively.
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induced CXCL8 and IL-6 release by 50% (Figure 5). In
contrast the negative control analogue of mastoparan
failed to reduce either CXCL8 or IL-6 release from LPS-
stimulated PBMCs.
Pertussis toxin and inhibition of NADPH oxidase prevents
LPS-induced phosphorylation of AKT
Pertussis toxin can completely inhibit LPS-induced
phosphorylation of AKT as demonstrated by Western
blotting (Figure 6). Stimulation of PBMCs with LPS
induced an almost 3-fold increase in AKT phosphoryla-
tion levels compared to non-treated cells (p <0 . 0 0 1 ) .
The compound apocynin specifically blocks NADP oxi-
dase 4 activity with an IC50 of 10 μM [30]. The increase
in AKT phosphorylation was completely inhibited by
pre-treatment of the PBMCs with either pertussis toxin
or the NADP oxidase 4 inhibitor, apocynin (Figure 5).
Discussion
We report here that stimulation of human PBMC by
LPS, leading to the release of pro-inflammatory
cytokines such as CXCL8 and IL-6, is dependent, in
part, on PI3K signalling. Moreover, the activation of
PI3K by LPS was G-protein dependent as the G protein
inhibitor, pertussis toxin, clearly blocked PI3K signalling.
However, neither pertussis toxin nor mastoparan could
completely prevent LPS induced cytokine release, indi-
cating multiple signalling pathways were at work. In
contrast to pertussis toxin, however, the anti-oxidant N-
acetylcysteine could only inhibit LPS-induced PI3K sig-
nalling by 50%.
T h ei n n a t ei m m u n es y s t e m ’s ability to initiate
responses to lipopolysaccharide (LPS) of Gram negative
organisms is effectively carried out upon the recognition
of LPS by the LPS-binding protein (LBP). LBP is an
acute-phase protein that binds to LPS and catalyses its
transfer to membrane-bound CD14 (mCD14), which is
a 55-kDa glycoprotein expressed on the surface of
monocytes in PBMCs. LPS is released from CD14 in the
lipid bilayer, and the intercalated LPS binds to a com-
plex of receptors such as the chemokine receptor 4
(CXCR4) and the heat shock proteins 70 and 90 [31]. A
complex of Toll-like receptor 4 (TLR4) and MD-2 is
Figure 2 PI3K inhibition prevents C5a-induced chemotaxis in human monocytes. Human monocytes were pretreated with wortmannin for
30 min and then allowed to migrate in response to 3 nM C5a. Data was normalised relative to control, where control represents 100%
chemotaxis in response to C5a only treatment. Results are displayed as mean ± SEM for 3 independent experiments and the sigmoidal dose
response curve plotted using Prism4 software.
Figure 3 A time course of LPS-induced phosphorylation of Akt in human PBMCs. PBMCs were treated with 100 ng/ml LPS and at defined
time points cells were harvested, lysed and assessed for the presence of Akt phosphorylation by Western blot. The blot is representative of the
experiment repeated at least 3 times.
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ways such as the NF-B. The activation of PI3K by LPS
through an apparent trimeric G-protein complex would
at first appear to be contradictory to current under-
standing, whereby only 7 transmembrane receptors are
able to signal through trimeric G-protein complex acti-
vating the PI3Kg isoform [32]. However, our results
show that there is clearly a link between TLR4 receptor
activation by LPS and G-protein dependent PI3K activa-
tion. A plausible explanation for this observation could
be the involvement of intracellular ROS generation
upon TLR4 activation by LPS. Once TLR4 is activated it
recruits the NADP-oxidase complex, NOX4. This com-
plex is then able to generate ROS in the form of hydro-
gen peroxide [7], which can activate PI3K [33]. The
proximity of this ROS generation close to the plasma
membrane would enable it to impact on other compo-
nents associated with the plasma membrane. As other
studies have demonstrated [34], ROS activates Gi and
Go trimeric G protein complexes releasing Gbg subunits
to activate downstream targets such as PI3Kg.W ep r e -
sent, therefore, a plausible mechanism to account for
the G-protein dependent PI3Kg activation as a result of
LPS stimulated ROS production (Figure 7).
ROS by their very nature are highly promiscuous and
will target numerous redox sensitive molecules. Indeed,
the protein tyrosine phosphatases are particularly sus-
ceptible to inhibition by ROS due to a key cysteine resi-
due within the active site [34]. This can lead to
deregulated activation of PI3K and therefore increased
phosphorylation of AKT [35]. When ROS was inhibited
by N-acetylcysteine in our experiments, we did not see
complete inhibition of PI3K activity. The explanation for
this may be two fold. Firstly, not all LPS-activated PI3K
is driven through ROS and secondly the N-acetylcys-
teine concentrations used were not as high as that
reported elsewhere, where up to 30 mM N-acetylcys-
teine was used. Moreover, in the experiments reported
Figure 4 LPS-induced phosphorylation of AKT is inhibited by wortmannin and N-acettylcysteine in a concentration-dependent manner
in human PBMCs. Human PBMCs were pre-treated with either (a) wortmanniun or (b) N-acetylcyteine for 30 minutes before stimulating with
LPS for 15 minutes. For each data point, the % of phosphorylated AKT relative to total AKT present is plotted as the mean ± SEM from at least 3
independent experiments. Sigmoidal dose response curves were plotted using Prism4 software. As a negative control, cells were left untreated.
Figure 5 LPS-induced release of (a) CXCL8 and (b) IL-6 in human PBMCs. Cells were pre-treated with either the G-protein inhibitor pertussis
toxin, the specific Gia inhibitor mastoparan (Mas+) or its inactive counterpart (Mas -). The data represents the mean ± SEM from 8 experiments.
*P < 0.05 as determined by Kruskal Wallace non-parametric ANOVA followed by Dunnets post-test analysis.
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volunteers were pretreated with either Apocynin (300 μM) or pertussis toxin (100 ng/ml) for 30 min before LPS stimulation. Phosphorylated AKT
and total AKT levels were visualised by Western blot and assessed semi-quantitatively by band densitometry. The data was normalised to total
AKT for each treatment group and plotted as mean ± S.E.M of 7 independent experiments (**p < 0.01 as determined by Kruskal Wallace non-
parametric ANOVA followed by Dunnets post-test analysis) showing the fold-increase in phospho-Akt compared to unstimulated cells.
Figure 7 Schematic representation of LPS-induced PI3K activity through apocynin sensitive NOX4 and pertusis toxin/mastoparan
sensitive Gi protein activation. N-acetyl cysteine neutralises any NOX4 generated intracellular superoxide which can trigger activation of ROS
sensitive Gi proteins releasing Gbg subunits to activate PI3Kg.
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pletely inhibit LPS-induced pAKT expression unlike
another anti-oxidant, a-tocopherol [11]. This suggested
that a compartmentalisation effect for the different anti-
oxidants, whereby N-acetylcysteine, unlike tocopherol,
could not penetrate the lipid compartment to neutralise
the ROS located there.
In conclusion, we have shown that LPS can activate
PI3Kg activity through a ROS and pertussis toxin sensi-
tive mechanism in human PBMC (Figure 7). Moreover,
this PI3K dependent pathway is responsible for at least
50% of the functional response seen with respect to
LPS-induced cytokine release from human PBMCs.
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